Trevena Inc. has entered into an Assignment and Release Agreement with Jiangsu Nhwa Pharmaceutical Co. Ltd. and R-Bridge Investment Four Pte. Ltd., effectively terminating and releasing Trevena from all obligations under a previous royalty-based loan agreement, except for indemnification and surviving obligations. In return, Trevena has agreed to transfer all rights, title, and interest under its Chinese License Agreement with Nhwa for royalties in China, except for commercialization milestone payments. The original loan agreement was entered into on March 30, 2022, and amended on July 3, 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevena Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-003726), on January 14, 2026, and is solely responsible for the information contained therein.